Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vaccine-Immunotherapy combo takes aim at Hard-to-Treat ovarian cancer

NCT ID NCT03113487

Ongoing Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether combining a vaccine that targets the p53 protein (p53MVA) with the immunotherapy drug pembrolizumab can shrink tumors in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to platinum-based chemotherapy. The vaccine helps the immune system recognize and attack cancer cells, while pembrolizumab removes the brakes on immune cells. The study measures how many patients have a complete or partial response and how long they live without the cancer growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a p53-targeting vaccine (p53MVA) combined with the immunotherapy drug pembrolizumab
What this could lead to
If successful, this combination could offer a new treatment option for patients with recurrent ovarian cancer that no longer responds to standard platinum-based chemotherapy.
What could go wrong
This is a small, early-phase trial, so results may not apply to all patients. The vaccine and immunotherapy combination may cause immune-related side effects, and the response rate may be low.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube carcinoma ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA RECURRENT PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.